Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Debt to Equity (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Debt to Equity for 12 consecutive years, with $0.61 as the latest value for Q4 2025.

  • Quarterly Debt to Equity rose 259.29% to $0.61 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.61 through Dec 2025, up 259.29% year-over-year, with the annual reading at $0.61 for FY2025, 259.29% up from the prior year.
  • Debt to Equity hit $0.61 in Q4 2025 for Coherus Oncology, up from $0.42 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $15.59 in Q1 2022 to a low of -$8.66 in Q2 2022.
  • Historically, Debt to Equity has averaged -$0.11 across 5 years, with a median of -$0.45 in 2024.
  • Biggest YoY gain for Debt to Equity was 2564.54% in 2022; the steepest drop was 1906.39% in 2022.
  • Year by year, Debt to Equity stood at $0.77 in 2021, then tumbled by 331.19% to -$1.79 in 2022, then rose by 27.71% to -$1.29 in 2023, then skyrocketed by 70.48% to -$0.38 in 2024, then surged by 259.29% to $0.61 in 2025.
  • Business Quant data shows Debt to Equity for CHRS at $0.61 in Q4 2025, $0.42 in Q3 2025, and $0.31 in Q2 2025.